Semin Thromb Hemost 2024; 50(06): 829-834
DOI: 10.1055/s-0044-1780507
Review Article

Venous Thrombosis in Airborne Viral Infections: Is Coronavirus Disease 2019 now Any Different from Influenza?

1   Section of Clinical Biochemistry, University of Verona, Verona, Italy
,
2   Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Sydney Centres for Thrombosis and Haemostasis, NSW Health Pathology, Westmead Hospital, Westmead, NSW Australia
3   Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW, Australia
4   School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia
,
5   Unit of Otolaryngology, Head and Neck Department, AOUI University of Verona, Verona, Italy
› Author Affiliations

Abstract

One of the hallmarks of coronavirus disease 2019 (COVID-19), particularly in complicated cases (i.e., requiring hospitalization or intensive care support), is persistent hemostasis activation, which may be associated with a vast array of thrombotic episodes involving both the arterial and venous systems. The renewed emphasis on the relationship between viral infections and venous thrombosis paves the way for determining whether a more common and often underestimated infection disease, such as influenza, may also be associated with a significant burden of venous thrombotic episodes, and how this eventual thrombotic risk compares to that seen in COVID-19, both in the past and with newer variants. Our review of studies comparing the burden of venous thromboembolism (VTE) in patients with COVID-19 or influenza revealed that the thrombotic risk appears to be significantly higher in patients with COVID-19 but remains certainly not meaningless in those with influenza, particularly in subjects infected by highly virulent strains (i.e., H1N1), in those who develop pneumonia and require intensive care support. In these specific clinical settings, the adoption of tailored thromboprophylaxis may be indicated though more studies are compellingly needed on this matter. As COVID-19 variants emerge, there is a possibility that the VTE burden of COVID-19 will decrease, and progress to that of other respiratory viruses.



Publication History

Article published online:
23 February 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med 2020; 8 (07) 497
  • 2 COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet 2022; 399 (10334): 1513-1536
  • 3 Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon. Ann Transl Med 2020; 8 (11) 693
  • 4 Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc 2021; 96 (01) 203-217
  • 5 Ortega-Paz L, Talasaz AH, Sadeghipour P. et al. COVID-19-associated pulmonary embolism: review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (08) 816-832
  • 6 Candeloro M, Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis. Semin Thromb Hemost 2023; 49 (01) 47-54
  • 7 Lippi G, Favaloro EJ. Epidemiology and predisposing factors of post-COVID venous thrombosis: a concise review. Semin Thromb Hemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1770051.
  • 8 Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta 2020; 507: 167-173
  • 9 Bouvier NM, Palese P. The biology of influenza viruses. Vaccine 2008; 26 (Suppl 4, Suppl 4): D49-D53
  • 10 Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis 2014; 14: 480
  • 11 Kaku Y, Okumura K, Padilla-Blanco M. et al; Genotype to Phenotype Japan (G2P-Japan) Consortium. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect Dis 2024; 24 (02) e82
  • 12 Ong DSY, de Man P, Verhagen T. et al. Airborne virus shedding of the alpha, delta, omicron SARS-CoV-2 variants and influenza virus in hospitalized patients. J Med Virol 2023; 95 (04) e28748
  • 13 Ehrenzeller S, Zaffini R, Pecora ND, Kanjilal S, Rhee C, Klompas M. Cycle threshold dynamics of non-severe acute respiratory coronavirus virus 2 (SARS-CoV-2) respiratory viruses. Infect Control Hosp Epidemiol 2024; (e-pub ahead of print). DOI: 10.1017/ice.2023.286.
  • 14 Lane G, Zhou G, Hultquist JF. et al. Quantity of SARS-CoV-2 RNA copies exhaled per minute during natural breathing over the course of COVID-19 infection. medRxiv 2023; (e-pub ahead of print). DOI: 10.1101/2023.09.06.23295138.
  • 15 Faust JS, Del Rio C. Assessment of deaths from COVID-19 and from seasonal influenza. JAMA Intern Med 2020; 180 (08) 1045-1046
  • 16 Mattiuzzi C, Lippi G. Timeline analysis of clinical severity of COVID-19 in the general population. Eur J Intern Med 2023; 110: 97-98
  • 17 Kollias A, Kyriakoulis KG, Lagou S, Kontopantelis E, Stergiou GS, Syrigos K. Venous thromboembolism in COVID-19: a systematic review and meta-analysis. Vasc Med 2021; 26 (04) 415-425
  • 18 Zuin M, Barco S, Giannakoulas G. et al. Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis. J Thromb Thrombolysis 2023; 55 (03) 490-498
  • 19 Xiao D, Tang F, Chen L, Gao H, Li X. Cumulative evidence for the association of thrombosis and the prognosis of COVID-19: systematic review and meta-analysis. Front Cardiovasc Med 2022; 8: 819318
  • 20 Poissy J, Goutay J, Caplan M. et al; Lille ICU Haemostasis COVID-19 Group. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020; 142 (02) 184-186
  • 21 Boyd S, Martin-Loeches I. The incidence of venous thromboembolism in critically ill patients with COVID-19 compared with critically ill non-COVID patients. Ir J Med Sci 2021; 190 (04) 1317-1320
  • 22 Dalager-Pedersen M, Lund LC, Mariager T. et al. Venous thromboembolism and major bleeding in patients with coronavirus disease 2019 (COVID-19): a nationwide, population-based cohort study. Clin Infect Dis 2021; 73 (12) 2283-2293
  • 23 Stals MAM, Grootenboers MJJH, van Guldener C. et al; Dutch COVID & Thrombosis Coalition (DCTC). Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients. Res Pract Thromb Haemost 2021; 5 (03) 412-420
  • 24 Doyle AJ, Hunt BJ, Sanderson B. et al. A comparison of thrombosis and hemorrhage rates in patients with severe respiratory failure due to coronavirus disease 2019 and influenza requiring extracorporeal membrane oxygenation. Crit Care Med 2021; 49 (07) e663-e672
  • 25 Lo Re III V, Dutcher SK, Connolly JG. et al. Association of COVID-19 vs influenza with risk of arterial and venous thrombotic events among hospitalized patients. JAMA 2022; 328 (07) 637-651
  • 26 Ward A, Sarraju A, Lee D. et al. COVID-19 is associated with higher risk of venous thrombosis, but not arterial thrombosis, compared with influenza: Insights from a large US cohort. PLoS One 2022; 17 (01) e0261786
  • 27 Dintakurti SH, Kamath S, Mahon C. et al. Pulmonary hypertension: the hallmark of acute COVID-19 microvascular angiopathy?. ERJ Open Res 2023; 9 (01) 00389-02022
  • 28 Bhoelan S, Codreanu C, Tichelaar V, Borjas Howard J, Meijer K. Exploring heterogeneity in reported venous thromboembolism risk in COVID-19 and comparison to other viral pneumonias: a systematic review and meta-regression. Res Pract Thromb Haemost 2023; 7 (05) 102146
  • 29 Gaddh M, Scott D, Wysokinski WE. et al. Comparison of venous thromboembolism outcomes after COVID-19 and influenza vaccinations. TH Open 2023; 7 (04) e303-e308
  • 30 Lee SY, Teo WZY, Lim CXQ. et al. Venous thromboembolism in an Asian COVID-19 cohort across 3 infection waves—a retrospective observational study. Res Pract Thromb Haemost 2023; 7 (07) 102218
  • 31 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)—part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
  • 32 Mattiuzzi C, Henry BM, Lippi G. Updated statistics on Influenza mortality. Diagnosis (Berl) 2023; ( e-pub ahead of print). DOI: 10.1515/dx-2023-0158.
  • 33 Obi AT, Tignanelli CJ, Jacobs BN. et al. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord 2019; 7 (03) 317-324
  • 34 Avnon LS, Munteanu D, Smoliakov A, Jotkowitz A, Barski L. Thromboembolic events in patients with severe pandemic influenza A/H1N1. Eur J Intern Med 2015; 26 (08) 596-598
  • 35 Agarwal PP, Cinti S, Kazerooni EA. Chest radiographic and CT findings in novel swine-origin influenza A (H1N1) virus (S-OIV) infection. AJR Am J Roentgenol 2009; 193 (06) 1488-1493
  • 36 LeCount ER. Disseminated necrosis of the pulmonary capillaries in influenzal pneumonia. JAMA 1919; 72 (21) 1519-1520
  • 37 Lippi G, Favaloro EJ. Strength of anticoagulation in moderate to severe COVID-19 illness: in medio stat virtus?. Semin Thromb Hemost 2023; 49 (01) 81-84